T he beneficial hemodynamic effects of angiotensin converting enzyme (ACE) inhibitors are well known and usually ascribed to the prevention of formation of angiotensin II by these agents. However, ACE inhibitors affect other neurohormonal systems as well, including those involved with bradykinin, enkephalins, and substance P,' and it is unclear to what extent actions not related to angiotensin II have hemodynamic consequences. Evaluation of the hemodynamic effects of blockade of the angiotensin II receptor can help to elucidate the mechanism of the response to ACE inhibition. While the angiotensin II receptor has previously been blocked with peptide compounds such as saralasin, saralasin is not orally active, has a short duration of action, and is a partial agonist. 2 Losartan is a new specific angiotensin II receptor antagonist with no agonist properties, and it provides the opportunity to study the consequences of blocking angiotensin II.3 Its hemodynamic effects have never before been evaluated in patients with congestive heart failure. The objective of the present study was to evaluate the hemodynamic and neurohormonal responses to the angiotensin II antagonist losartan, previously known as MK-954 and DuP 753, in patients with congestive heart failure. Methods
Patient Population
We studied 66 patients with symptomatic congestive heart failure. There were 55 men and 11 women, aged 34 to 80 years (mean, 61+1 years). All patients had a left ventricular ejection fraction less than 40% by radionuclide angiography (range, 8% to 39%; mean, 24+1%). The cause of heart failure was ischemic heart disease in 36 patients and dilated cardiomyopathy in 30 patients. Twenty-six patients were classified by New York Heart Association criteria as class II, 33 patients were class III, and 7 were class IV. Long-acting ACE inhibitors were not given for at least 14 days prior to the hemodynamic study. Thirty-two patients had received captopril in the month prior to study, and this was withheld for at least 3 days prior to evaluation. Fig 2) , but the decreases between 3 and 5 hours were also greater for patients who received 25 mg losartan than for patients who received 5, 10, or 150 mg of the drug. The peak decrease in blood pressure occurred between 4 and 12 hours, with a continued effect still seen at 24 hours after drug administration.
As expected with a vasodilator, the cardiac index ( Fig   3) increased after patients received 5 or 25 mg losartan. There were no marked changes in heart rate. The pulmonary capillary wedge pressure and the right atrial pressure both tended to decrease with the drug (Fig 4) .
Neurohormonal Changes
These hemodynamic actions were accompanied by neurohormonal changes (Fig 5) . In response to losar- This effect lasts at least 25 hours and is accompanied by progressive increases in plasma renin activity and angiotensin II plasma concentrations.5 Our findings in patients with congestive heart failure demonstrate that losartan exerts effects in these patients (with presumed endogenous activation of the reninangiotensin-aldosterone axis) that are similar to the effects previously noted in normal individuals given exogenous angiotensin II. In the present study, mean arterial pressure and systemic vascular resistance decreased in a dose-dependent manner, and the effects persisted through 24 hours. It is difficult to compare the extent of vasodilation following administration of losartan with that seen after administration of ACE inhibitors. Variations in doses used, the duration of action of the drugs, and the patient populations evaluated could all affect the findings. It is therefore not surprising that the reported hemodynamic effects of ACE inhibitors vary widely among studies. Teprotide given intravenously in eight patients with heart failure resulted (after 30 minutes) in a decrease of mean arterial pressure of 10 mm Hg, a decrease in left ventricular end-diastolic pressure of 6 mm Hg, and an increase in cardiac index of 0.4 L * min' . m2.6 These findings are very similar to the results of the present study. In contrast, 1.5 hours after administration of high doses of captopril (25 to 150 mg), Thus, it is impossible with the present study to determine whether the effects of the blockade of the angiotensin II receptor with losartan are quantitatively different than the consequences of inhibition of ACE.
Neurohormonal Response
In the 24 hours following losartan administration, we noted a compensatory increase in the plasma concentration of angiotensin II and plasma renin activity similar to that previously seen in normal individuals.5 As with the hemodynamic response, the peak inhibitory effect on aldosterone concentrations tended to be with the 25-mg dose. Unlike the hemodynamic response, however, angiotensin II concentrations and plasma renin activity tended to be greater in patients who received more than 25 mg losartan than in those who received a 25-mg dose. 
Study Limitations
The present study was an acute single-dose study, and the chronic effects of losartan need to be evaluated.
While 25 mg losartan appears to be the optimal dose in this study, it is possible that with repeated dosing a lower dose would yield similar optimal concentrations. In heart failure patients especially, abnormal hepatic and renal function often mandate smaller doses of a drug. 16 Of course, chronic use of losartan might also lead to receptor concentration changes and decreased efficacy of this dose. Just as P-receptor concentration and activity changes with 3-blockers,17 angiotensin II receptor concentration or activity may be altered by an antagonist. Further chronic studies of losartan in patients with heart failure will answer these questions.
Ideally, evaluation of an angiotensin II antagonist should be performed in patients not previously exposed to ACE inhibitors. We attempted to minimize the effects of ACE inhibitors by evaluating only patients who had not received ACE inhibitors long enough to eliminate plasma concentrations of these agents. Nevertheless, the prolonged effects of ACE inhibitors consequent to the long tissue half-life of ACE inhibitors18 may have decreased the acute effects observed in the present study.
This study evaluated 12 or fewer patients in each panel, and the power of the study was not strong enough to rule out any greater hemodynamic effects with the highest doses. However, the consistency of this and previous studies suggests that, at higher doses, the extent of the increase in neurohormonal activation is greater than any increase in vasodilator response. While this does not prove that neurohormones limit the hemodynamic response to high doses of losartan, such actions are important following administration of other vasodilators. 19 As with ACE inhibitors, an acute dose of losartan is a vasodilator in patients with congestive heart failure. Also analogous to ACE inhibitors, administration of doses above a certain threshold demonstrate very little additional effect. Only further studies will show whether these similar hemodynamic characteristics will translate into similar clinical utility.
